Invasive Fungal Infections in the Era of Biologics

Research output: Contribution to journalReview article

22 Scopus citations


With the advent and widespread use of immunomodulating biologic agents, emerging invasive fungal infections are reported increasingly. To date there is no reliable method to screen patients before starting anti-tumor necrosis factor (TNF) therapy to predict their risk for acquiring fungal infections, partly because most of these infections are de novo infections. Patients should be counseled about avoiding high-risk activities that are associated with the endemic mycosis in their geographic areas. Physicians should keep a high level of suspicion for endemic fungal infections when patients receiving anti-TNF therapy or other biologics present with pulmonary or systemic infections. Rapid diagnosis and initiation of antifungal therapy are of utmost importance.

Original languageEnglish (US)
Pages (from-to)279-286
Number of pages8
JournalClinics in Chest Medicine
Issue number2
StatePublished - Jun 1 2009


  • Adalimumab
  • Aspergillosis
  • Coccidioidomycosis
  • Etanercept
  • Histoplasmosis
  • Infliximab
  • Invasive mycoses
  • TNF-alpha

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Fingerprint Dive into the research topics of 'Invasive Fungal Infections in the Era of Biologics'. Together they form a unique fingerprint.

  • Cite this